This Is MS Multiple Sclerosis Community: Knowledge & Support

Like LittleLisa, I am in the clinical trial that compare Campath to Rebif. I also had a relaps after about 6 months, but was able to control the relapse with steroids. I had a second infusion one and a half years ago, and am now stabilized. I recently had an MRI of the brain C-spine and T-spine. Not only is there no active disease, scarring from my very first attack has improved.

According to my ...

I'd like to share with you that I received alemtuzumab (Campath trade name) in the hospital 26.04. - 30/04/2011 under the program CARE MS II extension study.

Side effects of alemtuzumab infusions continue after I get tired, the most troublesome are unpredictable spikes of fever and headache as a symptom of allergy to the drug - but you can survive it, while I have a long-term improvement in efficiency and nerve regeneration - that is, ...

The presentation on Alemtuzumab starts at 11'10''. The link has been posted elsewhere on the site already and is a very informative speech overall btw.

http://www.youtube.com/watch?v=ZunEIZ9F ... dded#at=15

Anybody know how involved taking Campath off label would be? I am guessing we are talking something more involved than getting a shot at the doctor's office? Days in the hospital? Cost?

Thanks,
Looking88

Are the best candidates for Campath young people with highly inflamatory MS?

I am hoping it has worked for those with few or no lesions also.

Thanks,
Looking88

Hello all,
I haven't really been on here for a while. Mostly because for the past two years my symptoms had quieted down and I was busy living an active life. I've been in the campath study for three years now. As I'd hoped for, I responded pretty well to the first two doses; (well not to the actual infusions they almost killed me) but once my body healed I felt like I might be ...

Genzyme which plans to announce pivotal results from its program evaluating Campath in multiple sclerosis later this year, is also interested in broadening its portfolio in this indication, said Dr Michael Panzara.

The company remains committed to researching the drug’s effect on the autoimmune system in light of certain side-effects seen in trials, said Panzara, who is group vice president of multiple sclerosis and immune diseases at Genzyme.

Campath (alemtuzumab) is a chemotherapy drug ...

April 14, 2011 12:00 PM Eastern Daylight Time 

Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease

Data Presented at 63rd Annual Meeting of the American Academy Of Neurology

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corp., a subsidiary of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), today reported additional five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial showing that nearly two-thirds of alemtuzumab treated patients remained free of ...

Genzyme, a subsidiary of sanofi-aventis Group announced today that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple sclerosis (MS) at the American Academy of Neurology's (AAN) 63rd Annual Meeting in Hawaii, April 9 - 16, 2011.

Included among the additional Phase 2 trial safety and efficacy data at AAN will be presentations on the clinically-active disease status of patients through five-years of patient follow-up ...

Ggenzyme’s experimental ms drug to profit investors only if it has success.
<shortened url>